ROCHESTER, Mich., Dec. 15, 2021 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, releases survey results detailing the factors that influence oncologists’ treatment selection and persistence in patients with anaplastic lymphoma kinase positive non-small cell lung cancer (ALK+ NSCLC), which occurs in just 5% of NSCLC patients with multiple first-line treatments approved by the U.S. Food and Drug Administration (FDA). The survey explores affordability dynamics, pharmaceutical manufacturers’ support, challenges faced by patients in staying on therapy, and reasons why patients may switch or discontinue treatment.
OptimizeRx Survey Addresses Treatment Selection, Discontinuation and Switching in Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer – an Indication with Limited Patient Population
Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.
